期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
An oral fluoropyrimidine agent S-1 induced interstitial lung disease:A case report 被引量:3
1
作者 Hiromichi Yamane masahide kinugawa +6 位作者 Shigeki Umemura Yasuhiro Shiote Kenichiro Kudo Toshimitsu Suwaki Haruhito Kamei Nagio Takigawa Katsuyuki Kiura 《World Journal of Clinical Oncology》 CAS 2011年第7期299-302,共4页
A 66-year-old Japanese man with pancreatic cancer received eleven courses of gemcitabine monotherapy.The tumor responded to gemcitabine until metastatic liver tumors progressed.Subsequently,he was treated with S-1,an ... A 66-year-old Japanese man with pancreatic cancer received eleven courses of gemcitabine monotherapy.The tumor responded to gemcitabine until metastatic liver tumors progressed.Subsequently,he was treated with S-1,an oral fluoropyrimidine anticancer agent,as salvage chemotherapy.Forty-two days after initiating S-1,he presented with dyspnea and fever.Chest computed tomography showed diffuse interstitial lesions with thickening of the alveolar septa and ground glass opacity.Serum KL-6 level was elevated to 1,230 U/mL and he did not use any other drugs except insulin.Thus,the development of interstitial lung disease(ILD)was considered to be due to S-1.Arterial blood oxygen pressure was 49.6 Torr in spite of oxygen administration(5 L/min).Steroid therapy improved his symptoms and the interstitial shadows on chest radiograph.Although S-1-induced ILD has mostly been reported to be mild,clinicians should be aware that S-1 has the potential to cause fatal ILD. 展开更多
关键词 CORTICOSTEROID therapy INTERSTITIAL lung disease PANCREATIC cancer S-1
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部